These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1259 related articles for article (PubMed ID: 25411132)

  • 1. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer.
    Afshar-Oromieh A; Avtzi E; Giesel FL; Holland-Letz T; Linhart HG; Eder M; Eisenhut M; Boxler S; Hadaschik BA; Kratochwil C; Weichert W; Kopka K; Debus J; Haberkorn U
    Eur J Nucl Med Mol Imaging; 2015 Feb; 42(2):197-209. PubMed ID: 25411132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic performance of
    Afshar-Oromieh A; Holland-Letz T; Giesel FL; Kratochwil C; Mier W; Haufe S; Debus N; Eder M; Eisenhut M; Schäfer M; Neels O; Hohenfellner M; Kopka K; Kauczor HU; Debus J; Haberkorn U
    Eur J Nucl Med Mol Imaging; 2017 Aug; 44(8):1258-1268. PubMed ID: 28497198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PSA levels, PSA doubling time, Gleason score and prior therapy cannot predict measured uptake of [68Ga]PSMA-HBED-CC lesion uptake in recurrent/metastatic prostate cancer.
    Verburg FA; Pfister D; Drude NI; Mottaghy FM; Behrendt FF
    Nuklearmedizin; 2017; 56(6):225-232. PubMed ID: 29044297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection Efficacy of Hybrid
    Einspieler I; Rauscher I; Düwel C; Krönke M; Rischpler C; Habl G; Dewes S; Ott A; Wester HJ; Schwaiger M; Maurer T; Eiber M
    J Nucl Med; 2017 Jul; 58(7):1081-1087. PubMed ID: 28209912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrated
    Lütje S; Cohnen J; Gomez B; Grüneisen J; Sawicki L; Rübben H; Bockisch A; Umutlu L; Pöppel TD; Wetter A
    Nuklearmedizin; 2017 Jun; 56(3):73-81. PubMed ID: 28401244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of [(18)F]DCFPyL and [ (68)Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer.
    Dietlein M; Kobe C; Kuhnert G; Stockter S; Fischer T; Schomäcker K; Schmidt M; Dietlein F; Zlatopolskiy BD; Krapf P; Richarz R; Neubauer S; Drzezga A; Neumaier B
    Mol Imaging Biol; 2015 Aug; 17(4):575-84. PubMed ID: 26013479
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Akdemir EN; Tuncel M; Akyol F; Bilen CY; Baydar DE; Karabulut E; Ozen H; Caglar M
    World J Urol; 2019 May; 37(5):813-821. PubMed ID: 30151600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined Early and Late [
    Hohberg M; Kobe C; Täger P; Hammes J; Schmidt M; Dietlein F; Wild M; Heidenreich A; Drzezga A; Dietlein M
    Mol Imaging Biol; 2019 Jun; 21(3):558-566. PubMed ID: 30105521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score.
    Verburg FA; Pfister D; Heidenreich A; Vogg A; Drude NI; Vöö S; Mottaghy FM; Behrendt FF
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):397-403. PubMed ID: 26563121
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Caroli P; Sandler I; Matteucci F; De Giorgi U; Uccelli L; Celli M; Foca F; Barone D; Romeo A; Sarnelli A; Paganelli G
    Eur J Nucl Med Mol Imaging; 2018 Nov; 45(12):2035-2044. PubMed ID: 29922948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. (68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate?
    Ceci F; Uprimny C; Nilica B; Geraldo L; Kendler D; Kroiss A; Bektic J; Horninger W; Lukas P; Decristoforo C; Castellucci P; Fanti S; Virgolini IJ
    Eur J Nucl Med Mol Imaging; 2015 Jul; 42(8):1284-94. PubMed ID: 25975367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Value of 68Ga-PSMA HBED-CC PET for the Assessment of Lymph Node Metastases in Prostate Cancer Patients with Biochemical Recurrence: Comparison with Histopathology After Salvage Lymphadenectomy.
    Rauscher I; Maurer T; Beer AJ; Graner FP; Haller B; Weirich G; Doherty A; Gschwend JE; Schwaiger M; Eiber M
    J Nucl Med; 2016 Nov; 57(11):1713-1719. PubMed ID: 27261524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of recurrent prostate cancer lesions before salvage lymphadenectomy is more accurate with (68)Ga-PSMA-HBED-CC than with (18)F-Fluoroethylcholine PET/CT.
    Pfister D; Porres D; Heidenreich A; Heidegger I; Knuechel R; Steib F; Behrendt FF; Verburg FA
    Eur J Nucl Med Mol Imaging; 2016 Jul; 43(8):1410-7. PubMed ID: 26993315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recurrent prostate cancer: combined role for MRI and PSMA-PET in
    Jannusch K; Bruckmann NM; Morawitz J; Boschheidgen M; Quick HH; Herrmann K; Fendler WP; Umutlu L; Stuschke M; Hadaschik B; Antoch G; Schimmöller L; Kirchner J
    Eur Radiol; 2024 Jul; 34(7):4789-4800. PubMed ID: 38038758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of Hybrid ⁶⁸Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy.
    Eiber M; Maurer T; Souvatzoglou M; Beer AJ; Ruffani A; Haller B; Graner FP; Kübler H; Haberkorn U; Eisenhut M; Wester HJ; Gschwend JE; Schwaiger M
    J Nucl Med; 2015 May; 56(5):668-74. PubMed ID: 25791990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Whole-Body Integrated [
    Guberina N; Hetkamp P; Ruebben H; Fendler W; Grueneisen J; Suntharalingam S; Kirchner J; Puellen L; Harke N; Radtke JP; Umutlu L; Hadaschik BA; Herrmann K; Forsting M; Wetter A
    Mol Imaging Biol; 2020 Jun; 22(3):788-796. PubMed ID: 31482413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions.
    Afshar-Oromieh A; Malcher A; Eder M; Eisenhut M; Linhart HG; Hadaschik BA; Holland-Letz T; Giesel FL; Kratochwil C; Haufe S; Haberkorn U; Zechmann CM
    Eur J Nucl Med Mol Imaging; 2013 Apr; 40(4):486-95. PubMed ID: 23179945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of PSMA PET/CT imaging in restaging of prostate cancer patients with low prostate-specific antigen levels.
    Kabasakal L; Demirci E; Nematyazar J; Akyel R; Razavi B; Ocak M; Aygun A; Obek C; Kural AR
    Nucl Med Commun; 2017 Feb; 38(2):149-155. PubMed ID: 27893589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of PET/CT and PET/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience.
    Afshar-Oromieh A; Haberkorn U; Schlemmer HP; Fenchel M; Eder M; Eisenhut M; Hadaschik BA; Kopp-Schneider A; Röthke M
    Eur J Nucl Med Mol Imaging; 2014 May; 41(5):887-97. PubMed ID: 24352789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 63.